Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL29065229 | 0.82 | SLC7A5 (0.46) | SIGMAR1ALDH1A1NPFFR1NPFFR2 | |
| SCHEMBL17906 | 0.82 | MEN1 (0.52) | KMT2AMEN1GAAALDH1A1TSHR | |
| Cyclopentane SCHEMBL8727534 | 0.80 | EPHX1 (0.49) | L3MBTL1SIGMAR1KMT2AMEN1GAA | |
| Succinimide SCHEMBL6525020 | 0.80 | DDB1 (0.41) | L3MBTL1SIGMAR1KMT2AMEN1GAA | |
| Methane SCHEMBL1486197 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAAALDH1A1TSHR | |
| SCHEMBL6603412 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAAALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL77819 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAAALDH1A1TSHR | |
| SCHEMBL6679504 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAAALDH1A1TSHR | |
| Bicarbonate SCHEMBL28028118 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAAALDH1A1TSHR | |
| SCHEMBL9464092 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4556026-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4552654-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| US-7081481-B2 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1189874-B1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | LILLY SA (ES) | 2005-01-26 | — | — | EP | disclosed |
| US-20040102521-A1 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY | 2004-05-27 | — | — | US | disclosed |
| US-6504052-B1 | 2-carboxycyclopropyl glycine derivatives, used as agonists of glutamate receptors for prophylaxis of psychological and nervous system disorders; anxiolytics; antidepressants; drug abuse; anticonvulsant, analgesic and antiemetic agents | ELI LILLY AND COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-6498180-B1 | SUCH AS 2-(3'-HYDROXYMETHYL-2'-CARBOXYCYCLOPROPYL)GLYCINE; MODULATING METABOTROPIC GLUTAMATE RECEPTOR; TREATING DISORDERS OF CENTRAL NERVOUS | ELI LILLY AND COMPANY | 2002-12-24 | — | — | US | disclosed |
| CN-1152914-A | Technetium-sulphonamide complexes, their use, pharmaceutical agents containing them, and process for producing the complexes and agents | SCHERING AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102521-A1 | Excitatory amino acid receptor modulators | GRM1, GRM2, GRIN1 | L3MBTL1 2983/4885SIGMAR1 167/4885KMT2A 1257/4885 |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | L3MBTL1 497/4885SIGMAR1 2873/4885KMT2A 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.